TScan Therapeutics Appoints Brian M. Silver, J.D., to Its Board of Directors

Prior to joining Freeline in 2018, Mr. Silver was Partner and Head of Biotechnology in the healthcare practice at Perella Weinberg Partners, a leading independent global advisory firm. Prior to Perella Weinberg, Mr. Silver held a number of positions in Morgan Stanley’s healthcare investment banking group, most recently as Managing Director from 1998 to 2013. He began his career in the corporate transactions group at Sullivan & Cromwell. His advisory experience spans dozens of transactions, including mergers and acquisitions, joint ventures and licenses, and capital raises across the equity, debt, convertible and royalty finance markets. Mr. Silver received a J.D. with honors from the University of Chicago Law School and a B.A. with honors from Harvard College.

“Brian brings over 25 years of strategic and financial expertise to our Board, having served as an advisor to many private and publicly-traded biotechnology and pharmaceutical companies, as well as operating experience at Freeline Therapeutics,” said David Southwell, Chief Executive Officer at TScan. “We look forward to working with Brian as we continue to advance the development of our growing portfolio of TCR-T cell therapies addressing both liquid and solid tumors to the clinic.”

“I am excited about the long-term potential of TScan’s proprietary target identification platform to discover novel TCR targets for use in TCR-T cell therapies for the treatment of cancers with high unmet need. TScan recently demonstrated the potential of its platform to rapidly identify relevant TCR targets as the first group to publish the T-cell targets of recovering COVID-19 patients, including many previously unknown targets,” said Mr. Silver. “I am honored to join the Board and help provide guidance as the Company transitions to a clinical-stage organization and enters a new period of growth.”

About TScan Therapeutics

TScan discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors, and other serious diseases. Our proprietary, high-throughput platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of highly efficacious TCR-Ts with minimal off- target effects. Lead program TSC-100 is expected to enter clinical development for liquid cancers in 2021, and the Company is advancing additional TCR-Ts for solid cancers. TScan was co-founded by Board Chair Christoph Westphal (Partner, Longwood Fund) based on pioneering research from the Elledge Lab at Brigham and Women’s Hospital. The Company has raised over $80 million to date from leading strategic collaborators and investors including Longwood Fund, Novartis Institutes for Biomedical Research, Astellas Venture Management, Novartis Venture Fund, Bessemer Venture Partners, GV, 6 Dimensions Capital, and Pitango Venture Capital.

For more information, please visit www.tscan.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005061/en/